CIK 0001819133 · Non-accelerated filer<br>Smaller reporting company
Tango Therapeutics, Inc.
Sign in to watch- Ticker
- TNGX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (857) 320-4900
- Business address
- 201 BROOKLINE AVENUE, SUITE 901, BOSTON, MA, 02215
- Former names
- BCTG Acquisition Corp.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,858,086
- in 6 filings, $1.9M under 10b5-1 plans
Net −$1,858,086. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 18 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-03 | Crystal Adam President, R&D | Sale 10b5-1 | −5,267 | $26.79 | $141K | 137,476 |
| 2026-08-03 | Crystal Adam President, R&D | Sale 10b5-1 | −21,733 | $27.35 | $594K | 115,743 |
| 2026-08-03 | Crystal Adam President, R&D | Option exercise · Stock Option (Right to Buy) 10b5-1 | −27,000 | 287,040 | ||
| 2026-07-01 | Crystal Adam President, R&D | Option exercise 10b5-1 | +27,000 | $5.20 | $140K | 142,743 |
| 2026-07-01 | Crystal Adam President, R&D | Sale 10b5-1 | −19,629 | $29.34 | $576K | 123,114 |
| 2026-07-01 | Crystal Adam President, R&D | Sale 10b5-1 | −7,371 | $30.25 | $223K | 115,743 |
| 2026-07-01 | Crystal Adam President, R&D | Option exercise · Stock Option (Right to Buy) 10b5-1 | −27,000 | 314,040 | ||
| 2026-06-19 | Azelby Robert Director | Grant or award | +5,740 | 5,740 | ||
| 2026-06-19 | Azelby Robert Director | Grant or award · Stock Option (Right to Buy) | +35,910 | 35,910 | ||
| 2026-06-05 | Ketchum John B Director | Grant or award | +4,000 | 24,937 | ||
| 2026-06-05 | Ketchum John B Director | Grant or award · Stock Option (Right to Buy) | +25,000 | 25,000 | ||
| 2026-06-05 | Calhoun Lesley Ann Director | Grant or award | +4,000 | 16,500 | ||
| 2026-06-05 | Calhoun Lesley Ann Director | Grant or award · Stock Option (Right to Buy) | +25,000 | 25,000 | ||
| 2026-06-05 | Rothenberg Mace Director | Grant or award | +4,000 | 41,500 | ||
| 2026-06-05 | Rothenberg Mace Director | Grant or award · Stock Option (Right to Buy) | +25,000 | 25,000 | ||
| 2026-06-05 | Lee Sung Director | Grant or award | +570 | 22,870 | ||
| 2026-06-05 | Lee Sung Director | Grant or award · Stock Option (Right to Buy) | +3,570 | 3,570 | ||
| 2026-06-01 | Crystal Adam President, R&D | Option exercise 10b5-1 | +27,000 | $5.20 | $140K | 142,743 |
| 2026-06-01 | Crystal Adam President, R&D | Sale 10b5-1 | −6,140 | $22.25 | $137K | 136,603 |
| 2026-06-01 | Crystal Adam President, R&D | Sale 10b5-1 | −20,860 | $23.06 | $481K | 115,743 |
Page 2 of 11 · 211 trades